In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative
Authors:
Open Access
- 1 April 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 62 (1) , 116-121
Abstract
Telavancin is a novel semi-synthetic lipoglycopeptide currently in late-stage clinical development for the treatment of serious infections due to Gram-positive bacteria. The objective of this study was to provide a baseline prospective assessment of its in vitro activity against a large and diverse collection of Gram-positive clinical isolates from Europe and Israel. Gram-positive clinical isolates, collected between October 2004 and December 2005 from 36 hospital laboratories in 15 countries, were tested by broth microdilution using CLSI methodology. In total, 3206 isolates were collected. Telavancin had potent activity against Staphylococcus aureus and coagulase-negative staphylococci (MIC range ≤0.015 to 2 mg/L), independent of resistance to methicillin or to multiple drugs. Telavancin had particularly strong activity against streptococcal isolates (MIC range ≤0.001 to 0.5 mg/L), including penicillin-resistant and multiple drug-resistant Streptococcus pneumoniae and erythromycin non-susceptible β-haemolytic and viridans group streptococci. Telavancin also had excellent activity against vancomycin-susceptible enterococci (MIC90 0.5 mg/L), and although its MICs were elevated against VanA strains (Enterococcus faecalis MIC90 8 mg/L and Enterococcus faecium MIC90 4 mg/L), its MIC90 was substantially lower than observed with available glycopeptides. Telavancin has potent in vitro activity against contemporary Gram-positive clinical isolates from diverse geographic areas in Europe and Israel.Keywords
This publication has 16 references indexed in Scilit:
- In Vitro Activity of Telavancin against Gram-Positive Clinical Isolates Recently Obtained in EuropeAntimicrobial Agents and Chemotherapy, 2007
- Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003–2004)Journal of Antimicrobial Chemotherapy, 2006
- Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 StudyAntimicrobial Agents and Chemotherapy, 2006
- In Vitro Activity of Linezolid against Key Gram-Positive Organisms Isolated in the United States: Results of the LEADER 2004 Surveillance ProgramAntimicrobial Agents and Chemotherapy, 2005
- Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive BacteriaClinical Infectious Diseases, 2005
- In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and Corynebacterium sppAntimicrobial Agents and Chemotherapy, 2004
- Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteriaJournal of Antimicrobial Chemotherapy, 2004
- Antimicrobial Resistance Trends and Outbreak Frequency in United States HospitalsClinical Infectious Diseases, 2004
- Factors Associated with Relative Rates of Antimicrobial Resistance amongStreptococcus pneumoniaein the United States: Results from the TRUST Surveillance Program (1998–2002)Clinical Infectious Diseases, 2003
- Antimicrobial Resistance in Key Bloodstream Bacterial Isolates: Electronic Surveillance with The Surveillance Network Database‐‐USAClinical Infectious Diseases, 1999